t-Butyl (R)-(-)-4-Cyano-3-hydroxybutyrate and process for its preparation

Abstract: t-Butyl (R)-(-)-4-cyano-3-hydroxybutyrate is disclosed having an optical purity of 99%ee or higher. A process for producing it consists of cyanogenation of a t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate (obtained by enantioselective hydrogenation of a t-butyl 4-chloro- or bromo-acetoacetate) in an aprotic polar solvent, by adding an aqueous solution of sodium or potassium cyanide and stirring at 15-100°C for 2 to 5 hours. Recrystallization of the resulting crude product gives the optically active compound with high optical purity. The product can be used as an intermediate for making medicines.

Description: This invention relates to t-butyl (R)-(-)-4-cyano-3-hydroxybutyrate which is useful as an intermediate of a variety of medicines. For example, this compound can be the precursor of 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, a lactone moiety which seems to be an active site of 3-hydroxy-3-methylglutaryl coenzyme A (hereinafter abbreviated as HMG-CoA) reductase inhibitors. (R)-(-)-4-Cyano-3-hydroxybutyric acid esters are known to be easily converted to the active lactone site of Compactin, Mevalotin and Pravastatin, which are considered to be useful as a cholesterol depressant or an HMG-CoA reductase inhibitor. For example, it is reported that an (R)-4-cyano-3-hydroxybutyric acid ester with its hydroxyl group protected with a trialkylsilyl group or a tetrahydropyranyl group is hydrolyzed to form an amide which is then treated with an acid to obtain (R)-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, as disclosed in U.S. Patent 4,611,067. It is also reported that an HMG-CoA reductase inhibitor containing a phosphorus atom in the molecule thereof is obtained by halogen exchange of methyl (S)-4-bromo-3-hydroxybutyrate prepared from isoascorbic acid with its hydroxyl group protected to obtain a corresponding iodide compound, which is then converted to a Wittig-Hornor reagent, followed by several additional steps, as disclosed in J. Med.Chem. , Vol. 33, p. 2952 (1990). EP 0 330 172 A discloses that a 4-cyano-3-hydroxybutyric acid derivative with its hydroxyl group protected is reacted with a malonic acid derivative to obtain a 6-cyano-3-oxohexanoic acid derivative, which is further led to a cholesterol biosynthesis inhibitor. Known processes for synthesizing optically active 4-cyano-3-hydroxybutyric esters include a process comprising leading arabinose or ascorbic acid as an asymmetric source to methyl ( S )-4-bromo-3-hydroxybutyrate according to the technique described in Acta Chem. Scand. , Vol. B37, p. 341 (1983) and, after protecting the hydroxyl group with a tetrahydropyranyl group, a trialkylsilyl group, an alkyl group, etc., reacting the protected compound with sodium cyanide according to the technique as disclosed in U.S. Patent 4,611,067 and a process comprising reacting L-ascorbic acid with hydrogen peroxide and calcium carbonate to form calcium L-threonate monohydrate and reacting the compound with hydrogen bromide to obtain a dibrominated compound, which is then led to a bromohydrin compound according to the process disclosed in Carbohydrate Res. , Vol. 72, p. 301 (1979), followed by the above-mentioned protection of the hydroxyl group and reaction with sodium cyanide. Preparation of ethyl 4-cyano-3-hydroxybutyrate is reported in Bull. Soc. Chim. Fr. , (4) 33 (1923), 732, which comprises hydrolyzing 4-chloro-3-hydroxybutyronitrile to obtain a carboxylic acid, converting the carboxylic acid into its ethyl ester, and reacting the ethyl ester with potassium cyanide. However, the yield reported is low, and the literature makes no mention of optical activity. The activity of the HMG-CoA reductase inhibitors is known to owe much to the steric configuration(s) of the hydroxyl group of the lactone moiety or of the two hydroxyl groups of the precursor β,δ-dihydroxycarboxylic acid. For example, reduction in inhibitory activity depending on the steric configuration of the hydroxyl group is mentioned e.g., in J. Med. Chem. , Vol. 30, p. 1858 (1987) and J. Org.Chem. , Vol. 51, p. 4931 (1986). That is, it is required to have high activity that the steric configuration of the hydroxyl groups at the β- and δ-positions of β,δ-dihydroxycarboxylic acid forms a cis -configuration. EP 0 024 348 A and U.S. Patents 4,611,068 and 4,855,481 describe that the 4-hydroxyl group of the lactone ring of Compactin or Mevinolin must have an ( R )-configuration to manifest the inhibitory activity and that conventional synthesis not only involves separation of the desired optically active compound which is accompanied with formation of an undesired isomer but also requires a very long reaction route. In view of these reports made to date, the conventional processes have required protection of a hydroxyl group or separation of an optically active compound and involved many steps for obtaining a lactone ring moiety having high inhibitory activity. It has therefore been desirable to develop an economical synthetic process which has a short reaction route and is easy to carry out. As a result of extensive investigations, the present inventors have found that t-butyl (R)-(-)-4-cyano-3-hydroxybutyrate, useful as an intermediate of medicines, can be obtained with ease by cyanogenation of a t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate which is easily obtained by enantioselective hydrogenation of a t-butyl 4-halogenoacetoacetate obtainable from diketene. The present invention has been completed based on this finding. The present invention relates to t-butyl (R)-(-)-4-cyano-3-hydroxybutyrate represented by formula (I): wherein Bu-t represents a t-butyl group. The present invention also relates to a process for preparing the said t-butyl (R)-(-)-4-cyano-3-hydroxybutyrate (I) comprising reacting a t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate represented by formula (II): wherein Bu-t is as defined above and X represents a chlorine atom or a bromine atom, with a cyanide represented by formula (III): MCN wherein M represents a sodium atom or a potassium atom. The starting compound, a t-butyl 4-halogenoacetoacetate, is easily obtainable from diketene according to known processes disclosed, e.g., in JP-A-61-146191 (the term "JP-A" as used herein means an unexamined published Japanese patent application) The optically active starting compound, a t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate, can be obtained by enantioselective hydrogenation of a t-butyl 4-halogenoacetoacetate in the presence of a ruthenium-optically active phosphine complex, e.g., Ru₂Cl₄(BINAP)₂(C₂H₅)₃N (wherein BINAP represents 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl), according to the process described in U.S. Patent 4,895,979. In this reaction, use of (R)-(+)-BINAP as a ligand of the ruthenium-optically active phosphine complex gives a desired (S)-compound. The optically active t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate may also be obtained from microorganism fermentation of a t-butyl 4-halogenoacetoacetate as described in JP-A-61-146191. The cyanogenation can be carried out by dissolving a t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate of formula (II) in an aprotic polar solvent, such as dimethylformamide, acetonitrile or dimethyl sulfoxide, adding an aqueous solution of a cyanide of formula (III) thereto, and stirring the mixture at a temperature in the range of from 15 to 100°C, and preferably from 40 to 70°C, for a period of from 2 to 5 hours, and preferably from 2 to 3 hours. The resulting reaction mixture is extracted with an organic solvent, e.g., ethyl acetate, toluene, diisopropyl ether or methylene chloride, the extract is washed with water, the solvent is removed by distillation, and the residue is recrystallized, e.g. from toluene, ethyl acetate, ethyl alcohol or isopropyl alcohol, to give a compound of the formula (I). One of the advantages provided by the present invention is a high optical purity of the compound of formula (I). While there is no easy means available for increasing the optical purity of other lower alkyl esters (e.g., the ethyl, propyl or n-butyl ester) due to their liquid character, the compound of formula (I), being a crystal, can be obtained with an increased optical purity by recrystallization which cannot be applied to the other esters. This is a novel feature of the present invention. Another advantage of the present invention resides in that the compound of formula (I) is less susceptible to saponification during cyanogenation than the other esters and therefore suffers from no great reduction in yield as encountered with the other esters. The present invention will now be illustrated in greater detail with reference to illustrative Examples and Comparative Examples. The percentages are by weight. Analyses of the compounds prepared were made with the instruments described below. ¹H-NMR: AMX-400 (400 MHz) (manufactured by Bruker, Inc.) Internal standard: tetramethylsilane Optical Rotation: DIP-360 (manufactured by JASCO Inc.) Optical Purity and Chemical Purity: High performance liquid chromatograph L-6000 (manufactured by Hitachi, Ltd) Detector: UV detector L-4000 UV (manufactured by Hitachi, Ltd.) IR Spectrum: IR-810 (manufactured by JASCO Inc.) Melting Point: Micro melting point apparatus (manufactured by Yanagimoto Seisakusho K.K.) The optical purity was obtained in terms of enantiomer excess (e.e.), which, in cases where a concentration of an ( R )-compound [ R ] is greater than that of an ( S )-compound [ S ], is calculated according to equation: %ee = {([ R ] - [ S ])/([ R ] + [ S ])} x 100 EXAMPLE 1 1) Preparation of t-Butyl ( S )-(-)-4-Chloro-3-hydroxybutyrate: In a 100 mℓ Hastelloy-made autoclave having been purged with nitrogen were charged 58.35 g (0.3 mol) of t-butyl 4-chloroacetoacetate and 120 mℓ of t-butyl alcohol, and solution of 250 mg (0.00015 mol) of Ru₂Cℓ₄[( R )-(+)-BINAP]₂Et₃N in 2 mℓ of methylene chloride was added thereto. The mixture was stirred at 100°C under a hydrogen pressure of 10 to 15 kg/cm² for 2 hours to conduct hydrogenation. The solvent was evaporated, and the residue was distilled under reduced pressure to give 53.0 g (percent yield: 90%) of t-butyl ( S )-(-)-4-chloro-3-hydroxybutyrate as a colorless clear liquid. The absolute configuration was determined by comparing with a known product. Optical purity: 92%ee Boiling Point: 113-116°C/2 mmHg [α] 25 / D = -94.7° (c=1.88, methanol) IR (neat)ν max (cm⁻¹): 3450, 2950, 1730, 1630 ¹H-NMR δ (ppm): 1.47 (9H, s), 2.55 (4H, m), 3.42 (1H, br s), 3.58 (2H, m), 4.22 (1H, m) 2) Preparation of t-Butyl ( R )-(-)-4-Cyano-3-hydroxybutyrate: In 120 mℓ of dimethyl sulfoxide was dissolved 36.7 g (0.22 mol) of the compound obtained in (1) above, and 45 mℓ of an aqueous solution containing 12.7 g (0.25 mol) of sodium cyanide was added thereto, followed by stirring at 65°C for 3 hours to give a conversion of 100%. The reaction mixture was extracted with 120 mℓ of ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was distilled to give 22.6 g (percent yield: 65%) of crude t-butyl ( R )-(-)-4-cyano-3-hydroxybutyrate. Optical Purity: 92%ee Boiling Point: 130-135°C/0.2mmHg Recrystallization of the crude product from 80 mℓ of toluene affgare 15.8 g of - t-butyl ( R )-(-)-4-cyano-3-hydroxybutyrate in a percent yield of 70% based on the crude product. Optical Purity: 99%ee or more Melting Point: 63-64°C [α] 25 / D = 2.09° (c=1.05, methanol) IR (KBr)ν max (cm⁻¹): 3450, 2950, 2260, 1730, 1630, 1190 ¹H-NMR (CDCℓ₃) δ (ppm): 1.46 (9H, s), 2.55 (2H, m), 3.45 (1H, br s), 3.59 (2H, dd, J=1.2, 5.6Hz), 4.21 (1H, m) COMPARATIVE EXAMPLE 1 Preparation of n-Butyl ( R )-(-)-4-Cyano-3-hydroxybutyrate In a 100 mℓ Hastelloy-made autoclave having been purged with nitrogen were charged 38.8 g (0.2 mol) of n-butyl 4-chloroacetoacetate and 50 mℓ of n-butyl alcohol, and solution of 73 mg of Ru₂Cℓ₂[( R )-(+)-BINAP]₂Et₃N in 2 mℓ of methylene chloride was added thereto. The mixture was stirred at 100°C under a hydrogen pressure of 11 to 12 kg/cm² for 2 hours to conduct hydrogenation. The solvent was evaporated, and the residue was distilled under reduced pressure to give 35.0 g (percent yield: 90%) of n-butyl ( S )-(-)-4-chloro-3-hydroxybutyrate. Optical purity: 94%ee Boiling Point: 118-120°C/2mmHg [α] 25 / D = -14.1° (c=1, chloroform) IR (neat)ν max (cm⁻¹): 3450, 2950, 1730, 1630 ¹H-NMR δ (ppm): 0.94 (3H, t, J=7.3Hz), 1.39 (2H, m), 1.62 (2H, m), 2.63 (4H, m), 4.14 (2H, t, J=6.7Hz), 4.35 (1H, m) The resulting compound was cyanogenated in the same manner as in Example 1-(2). That is, 58.5 g (0.3 mol) of n-butyl ( S )-(-)-4-chloro-3-hydroxybutyrate was dissolved in 180 mℓ of dimethyl sulfoxide, and 67.5 mℓ of an aqueous solution containing 16.7 g (0.34 mol) of sodium cyanide was added thereto, followed by stirring at 65°C for 2 hours. The reaction mixture was worked up in the same manner as in Example 1-(2) to obtain n-butyl ( R )-(-)-4-cyano-3-hydroxybutyrate in a percent yield of 58%. Optical Purity: 94%ee Boiling Point: 125°c/0.5mmHg [α] 25 / D = -23.5° (c=1.48, chloroform) IR (neat)ν max (cm⁻¹): 3450, 2950, 2260, 1730, 1630, 1190 ¹H-NMR (CDCℓ₃) δ (ppm): 0.94 (3H, t, J=7.3Hz), 1.39 (2H, m), 1.62 (2H, m), 2.63 (4H, m), 4.14 (2H, t, J=6.7Hz), 4.35 (1H, m) COMPARATIVE EXAMPLE 2 Preparation of Ethyl ( R )-(-)-4-Cyano-3-hydroxybutyrate In 120 mℓ of dimethyl sulfoxide was dissolved 36.7 g (0.22 mol) of ethyl ( S )-(-)-4-chloro-3-hydroxybutyrate which had been obtained in the same-manner as in Example 1 and Comparative Example 1, and 45 mℓ of an aqueous solution containing 12.7 g (0.25 mol) of sodium cyanide was added thereto. The mixture was stirred at 65°C for 2 hours to complete the reaction. The conversion attained was 90%. The reaction mixture was extracted with 120 mℓ of ethyl acetate, and the organic layer was washed with 400 mℓ of water and dried over anhydrous magnesium sulfate. The aqueous layer was extracted twice with 60 mℓ portions of ethyl acetate. The combined organic layers were dried, the solvent was removed by distillation, and the residue was distilled to furnish 20 g (percent yield: 57.5%) of ethyl ( R )-(-)-4-cyano-3-hydroxybutyrate. Optical Purity: 95.6%ee Boiling Point: 115°C/2mmHg [α] 20 / D = -27.0° (c=1.1, chloroform) IR (neat)ν max (cm⁻¹): 3450, 2970, 2260, 1730, 1630 ¹H-NMR (CDCℓ₃) δ (ppm): 1.29 (3H, t, J=7.2Hz), 2.63 (4H, br s), 3.42 (1H, br s), 4.20 (2H, q, J=7.2Hz), 4.34 (1H, m) COMPARATIVE EXAMPLE 3 Preparation of Propyl ( R )-(-)-4-Cyano-3-hydroxybutyrate In the same manner as in Comparative Example 2, propyl ( R )-(-)-4-cyano-3-hydroxybutyrate was obtained from propyl ( S )-(-)-4-chloro-3-hydroxybutyrate in a percent yield of 56.5% with an optical purity of 95%ee. Boiling Point: 110°C/0.3mmHg [α] 25 / D = -23.6° (c=1.1, chloroform) IR (neat)ν max (cm⁻¹): 3450, 2950, 2260, 1730, 1630, 1190 ¹H-NMR (CDCℓ₃) δ (ppm): 0.96 (3H, t, J=7.2HZ), 1.68 (2H, d, d, q, J=0.2, 6.7, 7.4Hz), 2.62 (4H, m), 4.10 (2H, t, J=6.7Hz), 4.34 (1H, m) According to the present invention, t-butyl ( R )-(-)-4-cyano-3-hydroxybutyrate can be obtained with high optical purity by cyanogenation of a t-butyl ( S )-(-)-4-halogeno-3-hydroxybutyrate which can be obtained by enantioselective hydrogenation of a t-butyl 4-halogenoacetoacetate easily obtainable from diketene. The present invention makes it feasible to prepare optically active t-butyl 4-cyano-3-hydroxybutyrate with an economic advantage on an industrial scale.

Claims: t-Butyl ( R )-(-)-4-cyano-3-hydroxybutyrate represented by formula (I): wherein Bu-t represents a t-butyl group. A process for preparing t-butyl ( R -(-)-4-cyano-3-hydroxybutyrate represented by formula (I): wherein Bu-t represents a t-butyl group, comprising reacting a t-butyl ( S )-(-)-4-halogeno-3-hydroxybutyrate represented by formula (II): wherein Bu-t is as defined above; and X represents a chlorine atom or a bromine atom, with sodium cyanide or potassium cyanide. A process as in Claim 2, wherein the reaction temperature is in the range of 15 to 100°C and the reaction period is from 2 to 5 hours. A process as in Claim 3, wherein the reaction temperature is from 40 to 70°C and the reaction period is from 2 to 3 hours. A process as in Claim 2, 3 or 4, wherein the t-butyl (S)-(-)-4-halogeno-3-hydroxybutyrate represented by formula (II) is dissolved in an aprotic polar solvent before the reaction with the cyanide. A process as in Claim 5, wherein the aprotic polar solvent is dimethylformamide, acetonitrile or dimethyl sulfoxide. A process as in any of claims 2 to 6, wherein the cyanide is present in the form of an aqueous solution.

Inventors: KUMOBAYASHI HIDENORI, MITSUHASHI SHIGERU, SAKURAI KAZUTOSHI, KUMOBAYASHI, HIDENORI, MITSUHASHI, SHIGERU, SAKURAI, KAZUTOSHI, KUMOBAYASHI, HIDENORI, C/O TAKASAGO INT. CORP., MITSUHASHI, SHIGERU, C/O TAKASAGO INT. CORP., Sakurai, Kazutoshi, c/o Takasago Int. Corp.
Applicants: TAKASAGO PERFUMERY CO LTD, TAKASAGO INTERNATIONAL CORPORATION
Application year: 1993
Main classification: C07C255
IPC codes: C07C255, C07C253